Overview
NuvoBio (Ottawa) is using an AI platform to speed up and de-risk peptide drug discovery.
What they’re doing: NuvoBio is de-risking production of new peptide therapies by using a drug discovery platform powered by AI that can quickly validate and fine tune potential new treatments.
How will this be used in the real world? Developing medications takes a long time, but what if AI could speed up the process? NuvoBio is using computational modelling to confirm the effectiveness of peptide therapies that can lead to quicker production of new medicines.